Annexon Shares Soar as ANX005 Meets Primary Endpoint in Phase 3 Trial for Guillain-Barré Syndrome

1. Annexon Shares Surge: Annexon's shares (ANNX) rose by 29% to 48% after the company announced positive results from its Phase 3 trial of ANX005 for Guillain-Barré Syndrome.
2. Phase 3 Trial Success: The Phase 3 trial of ANX005 met its primary endpoint, demonstrating the drug's effectiveness in reducing disability in patients with Guillain-Barré Syndrome.
3. Guillain-Barré Syndrome Treatment: ANX005 is a first-in-class C1q blocking antibody designed to treat Guillain-Barré Syndrome, a rare autoimmune disorder.
4. Conference Call and Webcast: Annexon held a conference call and webcast to discuss the topline Phase 3 results on Tuesday morning.
5. Regulatory Designations: ANX005 has received orphan drug designation and fast track designation from the Food and Drug Administration.